Medical and Chemical TOC Members

I, Emmanuel Addo-Yobo, nominated by UNEP Ozone Secretariat, residing in Ghana, and a member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8 . 
2. I am Professor in the Department of Child Health, Kwame Nkrumah University of Science and Technology, and Honorary Consultant Paediatrician with sub-specialty interest in paediatric pulmonology in the Directorate of Child Health, Komfo Anokye Teaching Hospital (KATH), Kumasi, Ghana. My responsibilities include general paediatric clinical care, clinical teaching and mentoring of undergraduate and postgraduate medical students, and research. I am the clinical consultant-in-charge of Paediatric Asthma Clinic KATH. I have been involved in many research activities on childhood asthma epidemiology in Ghana as Principal or Co-Investigator, some of which have been sponsored partly or fully by pharmaceutical companies.  I do not receive any form of remuneration from any drug companies. I have, however, given educational lectures to medical personnel on childhood asthma in Ghana which were sponsored by drug companies in a purely academic capacity. 
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   • Proprietary interests: I do not have any proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions:
     My business has an interest in the topics of the Montreal Protocol with regard to my patients with asthma and COPD who may be using MDIs containing ODS where there are no other affordable and effective alternatives.  My spouse is a business secretary working with a local financial institution in Ghana and has no interests in matters before the Protocol.
   • Government advice and other policy development: I served as a member of the National Expert Committee for the review of Standard Treatment Guidelines for Ghana (2016-2017). My role in this Committee included advising prescribers on safe and cost-effective treatments for asthma and COPD, and other disorders in my capacity as a clinician. I am also currently the chair of the National Poliomyelitis Expert Commitee (NPEC).
   • Paid research activities, fellowships or grants: I am not involved in any paid research activities, fellowships or grants relevant to the MCTOC activity. 
   • Other interests: None
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is the Ozone Secretariat of the United Nations Environmental Programme (UNEP).
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Professor Emmanuel Addo-Yobo 
Date: 16th April 2020

I, Fatima Al-Shatti, nominated by Kuwait, residing in Kuwait, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
   I am an Environment Advisor with the Kuwait Environment Public Authority.   I am providing government advice.to the Kuwait EPA.
2. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
3. My interests 1, and those of my personal partner and dependents, include the following 
   1. Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g., task forces).
   2. Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. 
   3. Employment, consultancy, directorship or other positions: Except for my part time work with Kuwait EPA as a consultant, neither I nor my family are employed by, do not consult for, and do not serve as a director of or hold any other position for any entity which has an interest in the subject matter of the Technology and Economic Assessment Panel.
   4. Government advice and other policy development: There are no conflicts between my member role and my role as a consultant to a government agency, Kuwait EPA.
   5. Paid research activities, fellowships or grants: No conflicts  
   6. Other interests: No conflicts   
4. The source of funding for my travel participation in the work of the Medical and Chemicals Technical Options Committee is UNEP’s Ozone Secretariat.
5. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines. 
6. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
7. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
8. I understand that this DOI will expire no later than one year after I have signed it.

Name: Fatima Al-Shatti
Date: 16th April 2021   

I, Paul J. Atkins, nominated by the United States of America and residing in the United States, a Member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I recently retired as Vice President at Oriel Therapeutics Inc (a Novartis company) and have established a consulting Company (Inhaled Delivery Solutions) that provides technical/regulatory guidance on the development of inhaled medicines. I am also Executive Chairman of a biotec start company (Nob Hill Therapeutics) which is developing a novel dry powder nebulizer.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner, include the following -
   1. Proprietary interests: None
   2. Financial interests: Shares in Novartis and my spouse owns shares in her former employer (GSK, a manufacturer of inhaled medicines)
   3. Employment, consultancy, directorship or other positions:  No current consulting interests
   4. Government advice and other policy development: None
   5. Paid research activities, fellowships or grants: None
   6. Other interests: N/A
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is my personal funds
6. Pursuant to paragraph 11 of the COI Guidelines I declare that I have declined to disclose information falling within paragraph 10 of those Guidelines and I undertake to ensure that I am completely excluded from discussions and decisions on topics related to the information that I have declined to disclose.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Paul J. Atkins PhD.
16th April 2021

I, William Auriemma, nominated by and residing in The United States of America, a Member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I serve as the Chie Executive Officer of Diversified CPC International, Inc., engaged in the supply of aerosol propellants to the consumer products industry. We do extensive work in determining commercial viability of “next generation” of propellant systems. My role as Past Chairman of the Household & Commercial Products Association allows for direct interaction with U.S. regulatory agencies.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests , and those of my personal partner and dependents, include the following:
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies.
   • Financial interests: I do not ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: My company works closely with major U.S. based manufacturers of low GWP substances and is the marketing and distribution arm of these products to the aerosol and medical device industries.
   • Government advice and other policy development: See above under Item c.
   • Paid research activities, fellowships or grants: None.
   • Other interests:
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is our company, Diversified CPC International, Inc. and they will bear all related costs.  There are no consulting fees involved.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have declined to disclose information falling within paragraph 10 of those Guidelines and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose. 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: William Auriemma
Date: 19th April 2021

I, Dr. Christian SEKOMO BIRAME, nominated by Rwanda Environmental Management Authority (REMA) / RWANDA, residing in RWANDA, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a the Director General of the National Industrial Research and Development Agency (NIRDA) and part time Lecturer at the University of Rwanda (UR) in the College of Science and Technology (CST) / School of Science (SoS) / Department of Chemistry. I use to teach the following modules:  Analytical Chemistry I & II; Environmental Chemistry I, Fundamental of waste management at undergraduate level and Water Quality Principles and Management; Wastewater Treatment and Disposal; Supervision of laboratory work and BSc final year project as well as MSC and PhD thesis. Beside my daily university workload I use to conduct many consultancies work for the Ministry of Environment and REMA mainly related with waste management in general (water quality analysis; Hazardous chemical waste management (POPs, PCBs and Hg). Recently I have worked with a team of IT specialist in the development of an IT system for ODS management in Rwanda for REMA.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests, and those of my personal partner and dependents, include the following: 
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). 
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.  
   • Employment, consultancy, directorship or other positions: I have an interest to conduct consultancy services in the topics of the Montreal Protocol because my potential client is also interested in these topics. I consult for an organisation that supports the Montreal Protocol in phasing out controlled substances.
   • Government advice and other policy development: See above under c.
   • Paid research activities, fellowships or grants: None
   • Other interests: None
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee will be provided by the Ozone Secretariat to support travel and accommodation when I will be attending MCTOC planned meetings.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.  
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Dr. Christian SEKOMO BIRAME
Date: 15th April 2021

I, Olga Blinova, nominated by the Russian Federation, residing in the Russian Federation, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a half-time, salaried employee at Federal State Institution “Saint Petersburg Pasteur Institute of Epidemiology and Microbiology” (St. Petersburg Pasteur Institute), at a laboratory which research. I work for the institution as a Research Fellow of the Laboratory of Zooanthroponoses. My responsibilities include studies in the area of the impact of climate change on epidemiology of zooanthroponoses.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents, include the following
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: No.
   • Government advice and other policy development: No.
   • Paid research activities, fellowships or grants: No.
   • Other interests: No
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is UNEP, Ozone Secreteriate.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines. 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Olga Blinova
Date: April 08, 2021

I, Steve Burns, nominated by Maria Belvisi, residing in UK, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Global Project Leader at Astrazeneca. My responsibilities include the development of new medicines for treatment of Respiratopry and Immunological illness.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests , and those of my personal partner and dependents, include the following
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I have shares in an entity with an interest in the subject matter of the meeting or work. I hold shares and share options with AstraZeneca
   • Employment, consultancy, directorship or other positions: I am employed by AstraZeneca
   • Government advice and other policy development: None
   • Paid research activities, fellowships or grants: None
   • Other interests: None
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is AstraZeneca
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Steve Burns
Date: 21st April 2021

I, Nicholas J. Campbell nominated by France, member of the Medical and Chemicals Technical Options Committee and CFC-11 Task Force, declare as follows:

1)   I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.

2)   I work for ARKEMA SA, based in Paris, as the Environment Manager for the Fluorinated Products Division.  

3)   This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.

4)   My interests include the following –

a.   Proprietary interests: I do not have a proprietary interest in a substance, technology or process (e.g., ownership of a patent) to be considered by the Technology and Economic Assessment Panel or any of its technical options committees or temporary subsidiary bodies.

b.   Financial interests: I have stock options in ARKEMA SA. ARKEMA SA is a producer of HCFCs, HFCs and HFOs.

c.   Employment, consultancy, directorship or other positions: I am Chairman of the European Fluorocarbon Technical Committee (EFCTC) that represents the producers of fluorocarbons in the European Union. I am also a member of the World Bank’s Ozone Operations Resource Group.

d.   Government advice and other policy development: I do not provide advice on significant issues to a government with respect to its implementation of the Montreal Protocol or engage in the development of significant policy positions of a government for a Montreal Protocol meeting.

e.   Paid research activities, fellowships or grants: I do not receive any paid research activities or any fellowships or grants for work related to a proposed use of an ozone-depleting substance or an alternative to a proposed use of an ozone depleting substance.

f.    Other interests: I do not have other interests related to the subject matter of the Technology and Economic Assessment Panel or the Montreal Protocol.

5)  ARKEMA SA supports my participation and travel on MCTOC and CFC-11 Task Force.

6)   Pursuant to paragraph 11 of the COI Guidelines I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines. 

7)   I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.

8)   I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee and CFC-11 Task Force.

9)   I understand that this DOI will expire no later than one year after I have signed it.

Signed: Nicholas J. Campbell (signed electronically by submission)
Date: 08th April, 2021

I, Andrea Casazza, nominated by MCTOC chair and residing in Italy, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am the R&D Head of Global CMC (Chemistry, Manufacturing & Controls) in Chiesi Farmaceutici SpA. My responsibilities include the Chemical, Pharmaceutical & Device development of new products
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents, include the following
   • Proprietary interests: I do not have any proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: NONE
   • Government advice and other policy development: NONE
   • Paid research activities, fellowships or grants: NONE
   • Other interests: NONE
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is Chiesi Farmaceutici S.p.A.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Andrea Casazza
Date: 16.04.2021

DOI 2021 Richard J. Cooke

I, Jin Fang, nominated by Ministry of Ecological Environment, residing in China , a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a professor of the Institute of Respiratory Diseases, Guangzhou Medical University. My responsibilities include research and development of inhalation preparation.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests , and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   • Proprietary interests: I have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). (add description of interest)
     I am one of the inventors of two MDIs related patents. In China, the patent inventor does not have the patent rights and interests. Although the patents have been authorized for many years, I have not obtained any economic benefits.
     Details of authorized patents are as follows:The invention relates to an inhalation pressure quantitative aerosol pharmaceutical composition and a preparation method thereof, Jin Fang; Wen Cong; Li Lixin; data of application: 2018-12-13.
   • A quantitative inhalation aerosol of benzcycloquinium bromide and its preparation method, Jin Fang; Zhao Shuqiang; Zhang Liu; data of application: 2009-04-08.
   • Financial interests: I (do not have) ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: (describe any interests relevant to the MCTOC activity).
     I am currently a professional committee member of 2 NGO. One is Chinese Pharmacopoeia Commission, in which I participate the revision of general principles of pharmaceutical preparation including inhaled products. The other is Chinese Pharmaceutical Association, I am the chairman of the Pharmaceutical Engineering Professional Committee and participating in the conference organization of pharmaceutical industry including inhaled preparations. And I am the PI in Institute of Respiratory Diseases, Guangzhou Medical University, engaged in inhalation related scientific research work.
   • Government advice and other policy development: (describe any interests relevant to the MCTOC activity, including any provision of advice to government, organisations or institutions involved in policy development)
     I drafted China's National Strategy for CFCs Elimination in MDIs and the Action Plan for Replacing Halon in Chinese Metered Dose Inhaler.
   • Paid research activities, fellowships or grants: (describe any paid research activities, fellowships or grants relevant to the MCTOC activity)
     I have been funded by the Chinese Pharmacopoeia Committee to draft the general principles of inhalation preparations, and funded by the Ministry of Science and Technology of the People’s Republic of China to carry out the research on the development inhaler products. Besides, I have been collaborated with Chinese pharmaceutical companies in some inhalation research, such as Joincare, Sitobio, Kingyork et al.
   • Other interests:
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is (describe funding arrangements and source )
   My funding for travel to meetings will be provided by UNEP's Ozone Secretariat.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I (have not) declined to disclose information falling within paragraph 10 of those Guidelines
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Jin Fang
Date: 22th, May, 2021

I, Maureen George, residing in United States, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am an Associate Professor at Columbia University School of Nursing. My responsibilities include leading an independent program of research in asthma, COPD and ILD in vulnerable populations, teaching in the PhD and master’s nursing programs, and meeting other service requirements.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests , and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: Honoraria received as a consultant to/speaker for Astra-Zeneca, Genentech Sanofi Genzyme/Regeneron, and Teva.
   • Government advice and other policy development: None
   • Paid research activities, fellowships or grants: Effort (salary) support on NIH grants studying behavioral interventions in asthma, COPD and ILD.
   • Other interests: None.
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is Columbia University. By “funding” I mean I will be paid my regular annual salary for the time spent on this committee work and will receive partial reimbursement for committee travel expenses. I will personally cover all other expenses relating to my work on behalf of the committee.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines. 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Maureen George
Date: 19th April 2021

I, Kathleen Hoffman, nominated by United States of America, residing in United States of America, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am employed by Sotera Health as Sr. Vice President of Global Environmental, Health and Safety. My responsibilities include leading the company’s global environmental, health, safety and security management program across the three difference Sotera business units.  Other responsibilities include oversight of various regulatory actions and participation with various government and trade association groups on regulatory and technical topics.  Sotera is a holding company that leads in the contract sterilization and testing services for the medical device and pharmaceutical industries. We utilize ethylene oxide and radiation for the sterilization and bio reduction of medical products, cosmetics and food products.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests , and those of my personal partner and dependents, include the following
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: See response to #2.
   • Government advice and other policy development: See response to #2.
   • Paid research activities, fellowships or grants:  None
   • Other interests:  None
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is by a voluntary basis.  However, such funding is very limited because my participation is mainly done on a remote basis.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have declined to disclose information falling within paragraph 10 of those Guidelines and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose. 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name:             Kathleen Hoffman
Date:               April 21, 2021

I, Jianxin HU, residing in China, a member of the Medical and Chemicals Technical Options Committee and of the Decision XXXI/3 Task Force on Unexpected Emissions of CFC-11, declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a professor in Peking University, Beijing China. My responsibilities include researching on environmental management on Chemicals.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests , and those of my personal partner and dependents, include the following:
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: (describe any interests relevant to the MCTOC activity).
   • Government advice and other policy development: I am advising the government to develop country program and sector plan for management of ODS and HFCs.
   • Paid research activities, fellowships or grants: researching on management of ODS and HFCs in China.
   • Other interests:
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is UNEP.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines. 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Jianxin HU
Date: April 15, 2021

I, Ryan Hulse, nominated by USA, residing in USA, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a Research and Development Director at Honeywell International. My responsibilities include leading the applications team in the development of new products in the areas Aerosol, Solvent, Refrigerants and Foam Blowing Agents.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests , and those of my personal partner and dependents, include the following
   • Proprietary interests: I have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). As part of my work at Honeywell I have developed aerosol and solvent alternatives to CFC and HCFCs.  These rights for the patents are wholly owned by Honeywell.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. 
   • Employment, consultancy, directorship or other positions: Honeywell has interest in the topics of the Montreal Protocol in that they are developing low global warming potential and non-ozone depletion potential alternatives to current CFC and HCFCs.
   • Government advice and other policy development: none
   • Paid research activities, fellowships or grants: none
   • Other interests:
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is from Honeywell Int.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I not declined to disclose information falling within paragraph 10 of those Guidelines
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Ryan Hulse
Date: April 19, 2021

I, Rabinder N Kaul, nominated by, and residing in India, appointed as member of the Medical and Chemicals Technical Options Committee and TEAP’s Task Force on Unexpected Emissions of CFC-11 under Decision XXXI/3 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I presently work for SRF Limited as a consultant. I am also Secretary of REGMA, an industrial association of refrigerant gases manufacturers in India.  My responsibilities include work related to the Montreal Protocol and related MEAs and the regulatory issues.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests, and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). 
   • Financial interests: I do have some shares in an entity with an interest in the subject
   • Employment, consultancy, directorship or other positions: I am also Secretary of the Refrigerant Gas Manufacturers Association (REGMA)
   • Government advice and other policy development: Do not provide advice on significant issues to a Government in respect of policy.
   • Paid research activities, fellowships or grants: I do not receive paid research activities or any fellowships /grants relevant to the TEAP activity.
   • Other interests: No other interests related to the subject matter of TEAP/Montreal Protocol
5. The source of funding for my participation in the work of the TOC and TEAP’s Task Force on Unexpected emissions of CFC 11. The travel and stay is funded by the Ozone Secretariat as Article 5 participant.   Professional services are however voluntary.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TOC and TEAP Temporary Subsidiary Body.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name:   Rabinder N Kaul
Date:    April 15, 2021

I, DR JAVAID AHMED KHAN nominated by PAKISTAN residing in PAKISTAN  as a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Professor and Consultant Chest Physician at the Aga Khan University. My responsibilities include taking care of patients with respiratory diseases including asthma and COPD. I also take part in educational activities involving doctors, medical students and general public. I am also involved in research work related to respiratory medicine and tobacco control.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.  YES
4. My interests , and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces)
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work
   • Employment, consultancy, directorship or other positions:  I am chair National Alliance for Tobacco control.
   • Government advice and other policy development: I do advise to government when my opinion is requested in relation with control of NCD in Pakistan. I advise government on various tobacco control measures. As Pulmonologist I do raise my voice on better quality of respiratory care and availability of low cost inhalers for asthma and COPD patients
   • Paid research activities, fellowships or grants:  As researcher I do receive grants from various funding agencies but mainly related to tobacco control in Pakistan
   • Other interests:  My other interests are climate change and global warming. I am a strong advocate for tree plantation in the country.
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee that involves travel is UNEP.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines (if have declined, add the following at the end of this statement “and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose”). 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Dr Javaid Khan
Date: May 19 2021

I, Andy Lindley, nominated by the United Kingdom, residing in the United Kingdom, a member of the Medical and Chemicals Technical Options Committee, and of the Decision XXXI/3 Task Force on Unexpected Emissions of CFC-11 declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am an independent consultant providing services to Koura Global and EFCTC. My responsibilities include the European Fluorocarbon Technical Committee (EFCTC) mainly focused on HFCs and HFOs, their applications and EFCTC website content development and newsletter production.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents, include the following
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: none.
   • Government advice and other policy development: none
   • Paid research activities, fellowships or grants: none
   • Other interests: no conflict
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is none as no funding is required for my participation as a corresponding member.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Andy Lindley
Date: 9 April 2021

I, Gerald McDonnell, nominated by United Kingdom, residing in United States, a Member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Senior Director at DePuySynthes, a Johnson & Johnson company. My responsibilities include microbiological quality and sterility assurance.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests , and those of my personal partner and dependents, include the following
   • Proprietary interests: I do not have) proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. I am a minor shareholder in Johnson & Johnson, a user of sterilization technology.
   • Employment, consultancy, directorship or other positions: I am an employee for Johnson & Johnson who uses radiation, heat and gas sterilization procedures for product manufacturing.
   • Government advice and other policy development: None.
   • Paid research activities, fellowships or grants: None.
   • Other interests: None
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is Johnson & Johnson.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Dr. Gerald McDonnell
Date: May 19, 2021

I, Robert J. Meyer, MD, nominated by the United States of America (USA), residing in the USA, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a Principal in Drug and Biological Products consulting at Greenleaf Health. My responsibilities include providing clients with strategic consulting to clients in dealing with the US Food and Drug Administration.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests , and those of my personal partner and dependents, include the following:
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: none
   • Government advice and other policy development: none
   • Paid research activities, fellowships or grants: none
   • Other interests:
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is personal funds supplemented for travel costs by my employer.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines. 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Robert J. Meyer, MD                                        
Date: April 16, 2021

I, Dr. B. Narsaiah, nominated by the Government of India, residing in India, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Dr. B. Narsaiah, Chief Scientist & Head (retired), Fluoroorganic division, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad – 500007, India. My responsibilities included development of technologies for ozone friendly chemicals and Synthesis of novel fluorinated molecules of biological interest. As I am superannuated from service, I am extending my expertise in Telangana state Environmental Impact Assessment Authority (TSEIAA) committee in giving environmental clearance to various projects like expansion of pharmaceutical industries, mines related to granites, sand, multiplex buildings under specified guidelines. 
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests1, and those of my personal partner and dependents, include the following 
   • Proprietary interests: I have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). (Development of technologies for alternatives to ozone depletion chemicals)
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work..
   • Employment, consultancy, directorship or other positions: I have an interest to extend consultancy services to the proposed activities in TEAP.
   • Government advice and other policy development: I have an interest to extend consultancy services to the proposed activities in TEAP. 
   • Paid research activities, fellowships or grants: Based on the options available to extend advisory services, I will coordinate paid research activities. 
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is through the Ozone secretariat of the Montreal Protocol, which will fund my participation .
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.  
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name:Dr.B.Narsaiah
Date:April20,2021

I, Timothy Noakes, nominated by United Kingdom, residing in United Kingdom, a (member/co-chair) of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am employed by Koura as a global technical expert in Medical Propellant gases. My responsibilities include providing technical support to pMDI industry.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests , and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. (add description of interest; relevant financial relationships between members should be disclosed)
   • Employment, consultancy, directorship or other positions: I am employed by Koura, the global leader in supplying medical propellants, and developing new ones.
   • Government advice and other policy development: None (describe any interests relevant to the MCTOC activity, including any provision of advice to government, organisations or institutions involved in policy development)
   • Paid research activities, fellowships or grants: None (describe any paid research activities, fellowships or grants relevant to the MCTOC activity)
   • Other interests:
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is paid by my employer.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines (if have declined, add the following at the end of this statement “and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose”). 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Timothy J. Noakes
Date:   08/04/2021

I, John G. Owens, nominated by United States of America, residing in United States of America, a member of the Medical and Chemicals Technical Options Committee and appointed by the Halons Technical Options Committee co-chairs as a Consulting Expert, declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a lead research specialist at 3M Company, Saint Paul, Minnesota, USA. My responsibilities include product development and environmental impact assessment for fluorinated fluid technologies, including cleaning and deposition solvents and aerosol components.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. I own shares of stock in my employer, 3M Company, which is an entity with an interest in the Montreal Protocol as a manufacturer of alternatives to ozone depleting substances. Should a conflict arise due to activities related to my employer, I will recuse myself as delineated in Decision XXIV/8.  
   • Employment, consultancy, directorship or other positions: Except for my employment at 3M Company, neither I nor my spouse are employed by, do not consult for, do not serve as a director of or hold any other position for any entity which has an interest in the subject matter of the Technology and Economic Assessment Panel.
   • Government advice and other policy development: Neither I nor my spouse provide advice on issues to a government with respect to its implementation of the Montreal Protocol or engage in the development of significant policy positions of a government for a Montreal Protocol meeting.
   • Paid research activities, fellowships or grants: None.
   • Other interests: None.
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee and the Halon Technical Options Committee is my employer, 3M Company.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines. 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee and a Consulting Expert to the Halon Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: John G. Owens
Date: 18 May 2021

I, José Ignacio Pons, residing in USA, a co-chair of the Decision XXXI/3 Task Force on Unexpected Emissions of CFC-11 and a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am president of Spray Quimica CA. My responsibilities include production of industrial aerosols.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents, include the following
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: None.
   • Government advice and other policy development: None
   • Paid research activities, fellowships or grants: None.
   • Other interests: Recovery of the Ozone layer and mitigation of Climate Change
5. The source of funding for my participation in the work of the Decision XXXI/3 Task Force on Unexpected Emissions of CFC-11 is None.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Decision XXXI/3 Task Force on Unexpected Emissions of CFC-11.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name:José Ignacio Pons
Date: April 19th 2021

I, John Pritchard, nominated by and residing in United Kingdom, a Member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am now acting as an independent consultant to clients developing respiratory drugs, delivery systems and digital healthcare, trading under the company name of Inspiring Strategies.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests , and those of my personal partner and dependents, include the following:
   • Proprietary interests: We do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: My wife and I have minority ownership of shares in various pharmaceutical companies who develop, manufacture and sell respiratory products that are impacted by decisions taken under the Montreal Protocol.
   • Employment, consultancy, directorship or other positions: I consult to a variety of clients, some of whom may be commercially impacted by decisions taken under the Montreal Protocol. In particular, I am a non-Executive Director for Cardiff Scintigraphics, and a Director of iPharma, both contract research organisations providing formulation development and testing of inhaled products. In addition, I am a Director of Acu-flow, a company developing novel nebuliser technology and sit on 3 scientific advisory Boards for companies involved in the development of respiratory therapies.
   • Government advice and other policy development: None
   • Paid research activities, fellowships or grants: None
   • Other interests: None
5. I receive no funding for my participation in the work of the Medical and Chemicals Technical Options Committee. Travel expenses might in the future be supported either by client relationships or the UK Government.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: JN Pritchard
Date: 8 Apr 2021

I, Rabbur Reza, nominated by Bangladesh (A5), a member of the Medical and Chemical Technical Options Committee, declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I work as full time Chief Operating Officer at Beximco Pharmaceuticals Ltd, Bangladesh and as Managing Director at Nuvista Pharma Ltd., Bangladesh. As the operational leader I am overseeing both Company’s business operations, which include pharmaceutical formulation and raw material manufacturing & quality control, research & development, regulatory affairs, training (learning & development management), sales, marketing and brand management, distribution, international business development, informational technology, medical affairs, project management, human resources etc.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests, and those of my personal partner and dependents, include the following: 
   • Proprietary interests: My employer Beximco Pharmaceuticals is the largest medical inhalers (MDI & DPI) manufacturer in Bangladesh and has an interest in the topics of Montreal Protocol, as it is engaged in development, manufacturing and marketing of MDIs in local and international markets. I have no proprietary interest in alternatives or substitutes to ODS.
   • Financial interests: I do not own stock in companies producing ODS or alternatives or substitutes to ODS, and do not have an interest in the outcome of essential use nominations.
   • Employment, consultancy, directorship or other positions: I work as full time Chief Operating Officer at Beximco Pharmaceuticals Ltd, Bangladesh and as Managing Director at Nuvista Pharma Ltd., Bangladesh. I also serve as a director on the board of BioCare Manufacturing Sdn Bhd., Malaysia. BioCare is involved in manufacturing MDIs. My spouse is a medical practitioner and has no interest in matters before the Protocol.
   • Government advice and other policy development: None.
   • Paid research activities, fellowships or grants: None.
   • Other interests: None.
5. UNEP’s Ozone Secretariat funds my travel expenses for participation on MTOC.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have declined to disclose information falling within paragraph 10 of those Guidelines and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose.  
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Rabbur Reza
Date: 21st April 2021

I, Raj SHARMA, nominated by Prof Woodcock (MTOC Chair), residing in UK, a (member/co-chair) of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Global Medical Affairs Lead at GSK. My responsibilities include Inhaler clinical development and communications
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests , and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   • Proprietary interests: I do not have a proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). (add description of interest)
   • Financial interests: I have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. GSK has an interest in low carbon inhaler inhalers including development and potential business partnerships  
   • Employment, consultancy, directorship or other positions: I am a paid employee of GSK
   • Government advice and other policy development: (describe any interests relevant to the MCTOC activity, including any provision of advice to government, organisations or institutions involved in policy development)
   • Paid research activities, fellowships or grants: (describe any paid research activities, fellowships or grants relevant to the MCTOC activity)
   • Other interests:
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is GSK as required
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines (if have declined, add the following at the end of this statement “and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose”). 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Raj Sharma
Date: 05 MAY 2021

I, David Sherry, residing in the United Kingdom of Great Britain and Northern Ireland, appointed as member of TEAP’s Task Force on Unexpected Emissions of CFC-11 under Decision XXX/3, and member of the Medical and Chemicals Technical Options Committee, declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Co-Director and co-owner of Nolan Sherry and Associates Ltd (NSA). NSA specialises in the chlorine and fluorine chemical industries, providing technical, commercial, strategic and regulatory advice to the chemical industry, trade associations and government organisations. My responsibilities have included studies on HFOs and CTC, chloromethanes, chloroethanes, the commercial outlook for CTC; technical expertise in patent law, due diligence audits of CDM beneficiaries, provision of estimated emission rates for various chlorocarbons to various atmospheric researchers, and various evaluation and monitoring projects for UNMFS, UNDP, and World Bank.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with these Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents, include the following
   • Proprietary interests: I do not have any proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. (co-owner of NSA Ltd, as described above)
   • Employment, consultancy, directorship or other positions: see above.
   • Government advice and other policy development: see above
   • Paid research activities, fellowships or grants: none
   • Other interests: none relevant:
5. The source of funding for my participation in the work of the TEAP Task Force on destruction technologies is the UK Department of Environment, Food, and Rural Affairs (DEFRA), who fund specific travel and hotel costs with limited DSA. As a self-employed consultant, the time, medical requirements for travel, and cost of my contribution to the CFC-11 Task Force and to MCTOC is self-funded
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have declined to disclose information falling within paragraph 10 of those and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose. 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP Temporary Subsidiary Body.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: David Sherry
Date: 20 April 2021

I, Peter Sleigh, nominated by, and residing in, the United Kingdom, a member of the Medical and Chemicals Technical Options Committee and TEAP’s Task Force on Unexpected Emissions of CFC-11 under Decision XXX/3 declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am employed as a Regulatory Manager for Koura, a producer and distributor of fluorinated products. My responsibilities include ensuring regulatory compliance particularly in Europe.  Koura has an interest in the topics of the Montreal Protocol because they sell fluorochemicals controlled by the protocol.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: On behalf of Koura I am Vice Chairman of European Fluorochemicals Technical Committee (EFCTC) an industry association for European fluorocarbon producers.
   • Government advice and other policy development: I do not provide advice on significant issues to a government with respect to its implementation of the Montreal Protocol or engage in the development of significant policy positions of a government for a Montreal Protocol meeting.
   • Paid research activities, fellowships or grants:- Except for my salary as an employee of Koura, I am not the recipient of any paid research activities or any fellowships or grants for work related to a proposed use of an ozone-depleting substance or an alternative to a proposed use of an ozone depleting substance.
   • Other interests: I do not have other interests related to the subject matter of the Technology and Economic Assessment Panel or the Montreal Protocol.
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee and TEAP’s Task Force on Unexplained Emissions of CFC-11 is as part of my day to day Regulatory Manager role for Koura.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Peter Sleigh
Date: 19th April 2021

I, Jørgen Vestbo, nominated by Ministry of Environment and Food of Denmark, residing in Denmark, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Professor of Respiratory Medicine at the University of Manchester, Manchester, UK. My responsibilities include research and teaching in respiratory medicine and management of patients; my area of focus is on chronic obstructive pulmonary disease (COPD) and inhaled therapies. I also see respiratory outpatients in a clinic in Copenhagen, Denmark.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests , and those of my personal partner and dependents, include the following:
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions:
     I have received honoraria from pharmaceutical companies (AstraZeneca, Boehringer-Ingelheim, Chiesi, GSK, Novartis and Teva) for advising and presenting. All work is being invoiced through a Danish tax registered one-man company, Vestbo medical, VAT Reg No 21215430.
     My son, Jakob Vestbo, is a Key account manager of Chiesi in Denmark.
     My wife, Inge Vestbo, worked from 1985 to 2009 in the pharmaceutical industry in Denmark and the UK.
     Government advice and other policy development: I am Chair of the Advocacy Council of the European Respiratory Society.
   • Paid research activities, fellowships or grants: I have previously held grants from GSK and together with a junior researcher in my group (Alexander Mathioudakis) I hold a grant from Boehringer-Ingelheim UK (£70,000).
   • Other interests: None.
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is personal (or from own NHS hospital endowment account).
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Jørgen Vestbo
Date: 11th April 2021

I, Kristine Whorlow, nominated by the Australian Government, residing in _Melbourne, Australia, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I retired as the CEO of the National Asthma Council Australia in 2017. My responsibilities included producing the national treatment guidelines for asthma and implementing these through an extensive national program of primary care health professional education as well as conducting national promotional campaigns to promote community education on asthma for patients and health professionals. I was also responsible for conducting outreach education activities in Asia Pacific. I am currently the First Vice President of the Global Airways and Allergy Patient Platform (GAAPP), the only global patient organisation in this field whose main role is to support existing and emerging patient organisations dedicated to patient support and advocacy in airways disease and allergy. I have recently joined the advisory board of a new medical respiratory device company, Respia.
3. My responsibilities on the board of GAAPP and the advisory board of Respia include general advice on governance, financial management, strategic planning, communication and the respiratory field.
4. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
5. My interests , and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: none relevant.
   • Government advice and other policy development: I occasionally provide general advice to the National Asthma Council Australia on some of the issues considered by MCTOC, e.g. GWP of inhalers, based on MCTOC’s published reports.
   • Paid research activities, fellowships or grants: none.
   • Other interests: none relevant.
6. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is my personal cost.
7. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
8. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
9. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
10. I understand that this DOI will expire no later than one year after I have signed it.

Name: Kristine Whorlow AM
Date: April 21, 2021

I, Gerallt Williams, nominated by Steve Cowperthwaite, residing in UK, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am (describe your affiliations, including job title, employer organization). My responsibilities include (describe current work interests/areas of focus).
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests , and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   • Proprietary interests: I (have/ do not have) proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). (add description of interest)
   • Financial interests: I (have/ do not have) ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. (add description of interest; relevant financial relationships between members should be disclosed)
   • Employment, consultancy, directorship or other positions: (describe any interests relevant to the MCTOC activity).
   • Government advice and other policy development: (describe any interests relevant to the MCTOC activity, including any provision of advice to government, organisations or institutions involved in policy development)
   • Paid research activities, fellowships or grants: (describe any paid research activities, fellowships or grants relevant to the MCTOC activity)
   • Other interests:
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is (describe funding arrangements and source )
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I (have/have not) declined to disclose information falling within paragraph 10 of those Guidelines (if have declined, add the following at the end of this statement “and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose”). 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Gerallt Williams
Date: 21 April 2021

I, Ashley Woodcock, residing in United Kingdom, appointed to the Technology and Economic Assessment Panel, co-chair of the Decision XXXI/7 Task Force on the continued provision of information on energy efficient and low-global warming technologies, and member of the Decision XXXI-1TEAP Task Force on Replenishment of the Multilateral Fund: declare as follows,

1) I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.

2) I am a Consultant Respiratory Physician and Professor of Respiratory Medicine.

3) This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.

4) My interests, and those of my personal partner and dependents include the following:  I am a member of the NW Lung Centre Charity and Chairman of its subsidiary Medicines Evaluation Unit. I am Chairman of Axalbion which is developing a new oral cough medicine (in Phase 1). I am Chairman of Reacta which is developing diagnostic tests for Food Allergy. None of these have any interest in relation to the Montreal Protocol, TEAP, MCTOC, or its Task Forces.

• Proprietary interests: I do not have proprietary interest in the subject matter of the Montreal Protocol, TEAP, MCTOC, or any Task Force.
• Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the Montreal Protocol, TEAP, MCTOC, or any Task Force.
• Employment, consultancy, directorship or other positions:  I occasionally consult on new medicines for pharmaceutical companies. None of these interests have any relation to the Montreal Protocol, TEAP, MCTOC, or any Task Force.
• Government advice and other policy development: I am on an advisory panel on the phase down of HFC inhalers for UK NHS Sustainability, and am Clinical Sustainability Lead for the Manchester University NHS Foundation Trust and associated hospitals.  No other relevant activity
• Paid research activities, fellowships or grants: None relevant
• Other interests: None relevant

5) The source of funding for my participation in the work of TEAP is Manchester University NHS Foundation NHS Trust, which allows me to take leave and provides travel support to attend meetings

6)   Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines. 

7)   I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.

8)   I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP body.

9)   I understand that this DOI will expire no later than one year after I have signed it.

Signed: Ashley Woodcock
Jan 1 2021

I, Nee Sun CHOONG KWET YIVE, nominated by the Government of Mauritius, residing in Mauritius, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Associate Professor in Chemistry at the University of Mauritius. My responsibilities include teaching Physical and Analytical at undergraduate and post graduate levels and doing research in the field of environmental chemistry.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests , and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: None
   • Government advice and other policy development: I participated in national meetings organized by Ministry of Environment, Mauritius to phase out ODSs.
   • Paid research activities, fellowships or grants:None
   • Other interests: None
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is (describe funding arrangements and source )
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Nee Sun Choong Kwet Yive
Date: 19 April 2021

I, ZHANG Lifei, nominated by China, residing in China, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a Professor of National Research Center for Environmental Analysis and Measurement in China. My responsibilities include: Laboratory use and standard analytical method on carbon tetrachloride; Persistent organic pollutants unintentionally produced during tetrachloroethylene production; Chemical decomposition technologies on organic compounds and it’s mechanisms; Environmental monitoring on POPs, mercury, and ODS.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents, include the following
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: None.
   • Government advice and other policy development: None.
   • Paid research activities, fellowships or grants: None.
   • Other interests: None.
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is supported by UNEP.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines. 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: ZHANG Lifei
Date: 12th April, 2021